Lyell Immunopharma, Inc.Lyell Immunopharma, Inc.Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪706.18 M‬USD
−0.91USD
‪−234.63 M‬USD
‪130.00 K‬USD
‪118.44 M‬
Beta (1Y)
3.13

About Lyell Immunopharma, Inc.

CEO
Lynn Seely
Website
Headquarters
South San Francisco
Employees (FY)
224
Founded
2018
FIGI
BBG00RNXFN14
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of LYEL is 2.77 USD — it has increased by 2.21% in the past 24 hours. Watch Lyell Immunopharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Lyell Immunopharma, Inc. stocks are traded under the ticker LYEL.
LYEL stock has fallen by 0.36% compared to the previous week, the month change is a 14.46% rise, over the last year Lyell Immunopharma, Inc. has showed a 3.82% decrease.
We've gathered analysts' opinions on Lyell Immunopharma, Inc. future price: according to them, LYEL price has a max estimate of 9.00 USD and a min estimate of 6.00 USD. Watch LYEL chart and read a more detailed Lyell Immunopharma, Inc. stock forecast: see what analysts think of Lyell Immunopharma, Inc. and suggest that you do with its stocks.
LYEL reached its all-time high on Sep 7, 2021 with the price of 19.84 USD, and its all-time low was 1.32 USD and was reached on Oct 9, 2023. View more price dynamics on LYEL chart.
See other stocks reaching their highest and lowest prices.
LYEL stock is 3.92% volatile and has beta coefficient of 3.13. Track Lyell Immunopharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Lyell Immunopharma, Inc. there?
Today Lyell Immunopharma, Inc. has the market capitalization of ‪706.18 M‬, it has increased by 4.89% over the last week.
Yes, you can track Lyell Immunopharma, Inc. financials in yearly and quarterly reports right on TradingView.
Lyell Immunopharma, Inc. is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
LYEL earnings for the last quarter are −0.24 USD per share, whereas the estimation was −0.22 USD resulting in a −8.77% surprise. The estimated earnings for the next quarter are −0.20 USD per share. See more details about Lyell Immunopharma, Inc. earnings.
Lyell Immunopharma, Inc. revenue for the last quarter amounts to ‪3.00 K‬ USD despite the estimated figure of ‪1.00 K‬ USD. In the next quarter revenue is expected to reach 0 USD.
LYEL net income for the last quarter is ‪−60.67 M‬ USD, while the quarter before that showed ‪−52.93 M‬ USD of net income which accounts for −14.62% change. Track more Lyell Immunopharma, Inc. financial stats to get the full picture.
No, LYEL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 25, 2024, the company has 224.00 employees. See our rating of the largest employees — is Lyell Immunopharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Lyell Immunopharma, Inc. EBITDA is ‪−222.69 M‬ USD, and current EBITDA margin is ‪−177.29 K‬%. See more stats in Lyell Immunopharma, Inc. financial statements.
Like other stocks, LYEL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Lyell Immunopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Lyell Immunopharma, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Lyell Immunopharma, Inc. stock shows the buy signal. See more of Lyell Immunopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.